Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-22-001627
Date:2022-01-03
Issuer: REATA PHARMACEUTICALS INC (RETA)
Original Submission Date:

Reporting Person:

RUFF SHAMIM
5320 LEGACY DRIVE
PLANO, TX 75024

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
CLASS A COMMON STOCK 2022-01-03 A 118 a $27.32 118 direct
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 27.32 2022-01-03 deemed execution date A 199 (a) 2032-01-03 class a common stock 199 $27.32 199 direct
Footnotes
IDfootnote
f1 the shares represent restricted stock units (rsu), which vest on june 8, 2022, subject to continued service through the vesting date.
f2 these rsus were issued to the reporting person pursuant to the reata non-employee director compensation policy in lieu of director fees of $3,225.
f3 the options vest in 2 equal installments on march 10, 2022 and june 10, 2022, subject to continued service through each vesting date.
f4 these options were issued to the reporting person pursuant to the reata non-employee director compensation policy in lieu of director fees of $3,225.

Elevate your investments